Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Medication


Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis

February 17th 2022

SGLT2i can be a valid therapeutic strategy for patients with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Journal of Diabetes Research)

Categories: Medication, News
Tags: SGLT2 inhibitors, uric acid

Categories: Medication
Tags: SGLT2 inhibitors, uric acid

Cardiovascular and Renal Outcomes with Canagliflozin in Patients with Peripheral Artery Disease: Data from the CANVAS program and CREDENCE trials

February 16th 2022

Patients with T2D and PAD derived similar relative cardiorenal benefits from canagliflozin treatment but higher absolute benefits compared to those without PAD, with no increase in MALE (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: canagliflozin

Categories: Cardiovascular, Medication, Nephropathy
Tags: canagliflozin

Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes

February 16th 2022

Empagliflozin may reduce steatosis but not fibrosis risk in individuals with type 2 diabetes and cardiovascular disease. The improvements in cardiorenal outcomes and mortality associated with empagliflozin therapy appear to be independent of steatosis and fibrosis risk (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Hepatology, Medication, Nephropathy, News
Tags: Empagliflozin, fibrosis, steatosis

Categories: Cardiovascular, Hepatology, Medication, Nephropathy
Tags: Empagliflozin, fibrosis, steatosis

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study

February 16th 2022

Liraglutide had beneficial actions on glycemic parameters and cardiometabolic risk factors in both non-obese and obese patients with T2DM, with a greater efficacy in the latter (Diabetes Therapy)

Categories: Cardiovascular, Medication, News
Tags: liraglutide, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: liraglutide, Type 2 Diabetes

Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME

February 14th 2022

Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four months of the trial after the last THR-149 injection with no rescue treatment required
These gains were seen in patients that are part of the 40-50% of DME patients that suboptimally respond to standard of care anti-VEGF therapy (Oxurion)

Categories: Medication, News, Ophthalmology
Tags: DME

Categories: Medication, Ophthalmology
Tags: DME

Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study

February 14th 2022

We found no evidence that metformin was associated with risk of AMD in primary care patients requiring treatment for type 2 diabetes (BMJ)

Categories: Medication, News, Ophthalmology
Tags: AMD, Type 2 Diabetes

Categories: Medication, Ophthalmology
Tags: AMD, Type 2 Diabetes

Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes

February 11th 2022

Canagliflozin reduces visceral adipose tissue and improves blood glucose, insulin resistance and systemic inflammation in people with newly-diagnosed type 2 diabetes (BMC Endocrine Disorders volume)

Categories: Medication, News
Tags: canagliflozin, Insulin resistance, metformin, Type 2 Diabetes

Categories: Medication
Tags: canagliflozin, Insulin resistance, metformin, Type 2 Diabetes

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. The SURPASS-5 Randomized Clinical Trial

February 9th 2022

Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks (JAMA)

Categories: Medication, News
Tags: glargine, glycaemic control, insulin, tirzepatide, Type 2 Diabetes

Categories: Medication
Tags: glargine, glycaemic control, insulin, tirzepatide, Type 2 Diabetes

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

February 8th 2022

Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: semaglutide, Type 2 Diabetes

Categories: Medication
Tags: semaglutide, Type 2 Diabetes

Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations

February 4th 2022

The use of a personalized approach in the management of people with T2D can reduce the cost and failure associated with the algorithmic “one-size-fits-all” approach, to anticipate disease progression, improve the response to diabetes pharmacotherapy and reduce the incidence of diabetes-associated complications (Metabolic Syndrome and Obesity)

Categories: Medication, News, Treatment
Tags: Type 2 Diabetes

Categories: Medication, Treatment
Tags: Type 2 Diabetes

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes

February 2nd 2022

SGLT2i and SGLT2i/GLP-1RA combination regimens may be beneficial in primary prevention of MACCE and HF and GLP-1RA for HF. These data call for primary prevention trials using these agents and their combination (Diabetes Care)

Categories: Cardiovascular, Medication, News
Tags: GLP-1 receptor agonists, heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: GLP-1 receptor agonists, heart failure, SGLT2 inhibitors, Type 2 Diabetes

Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study

January 27th 2022

Our findings suggest protective association of genetically proxied ACE inhibition with diabetes, while genetic proxies for BBs and CCBs possibly relate to an unfavourable metabolic profile (Diabetologia)

Categories: Cardiovascular, Hypertension, Medication, News
Tags: antihypertensives

Categories: Cardiovascular, Hypertension, Medication
Tags: antihypertensives

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors

January 27th 2022

The ESC recently added SGLT2 inhibitors to the management guidelines for HFrEF following good outcomes from DAPA-HF [18] and EMPEROR-Reduced [19] over the last 2 years. We hope that further supporting evidence for SGLT2 inhibitors in the management of HFpEF follows with the results of the ongoing DELIVER trial expected soon, and that as a result similar changes to guidelines may be added to support the use of SGLT2 inhibitors in the management of HFpEF (Diabetes Therapy)

Categories: Cardiovascular, Medication, News
Tags: heart failure, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: heart failure, SGLT2 inhibitors

ZT-01 – A Novel Somatostatin Receptor Antagonist for Restoring the Glucagon Response to Hypoglycemia in Type 1 Diabetes

January 23rd 2022

We conclude that ZT-01 may be effective in restoring glucagon responses and preventing the onset of hypoglycemia in patients with T1D (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: glucagon, hypoglycemia, Type 1 Diabetes

Categories: Medication
Tags: glucagon, hypoglycemia, Type 1 Diabetes

ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes

January 21st 2022

Interest in the potential for precision medicine in the prevention, treatment, and ongoing management of diabetes continues to grow across many of the most important stakeholder groups, including people with diabetes (Diabetes Care)

Categories: Medication, News, Treatment
Tags: ADA

Categories: Medication, Treatment
Tags: ADA

Insulin-GLP-1 receptor agonist relay and GLP-1 receptor agonist first regimens in individuals with type 2 diabetes: a randomized, open-label trial study

January 17th 2022

The GLP-1 receptor agonist is overall effective without prior glycemic control with insulin in participants with poorly controlled type 2 diabetes. However, in participants with insulinopenic type 2 diabetes, prior glycemic control with insulin may overcome glucose toxicity-induced GLP-1 resistance (Journal of Diabetes Investigation)

Categories: Medication, News
Tags: GLP-1 Receptor Agonist, Type 2 Diabetes

Categories: Medication
Tags: GLP-1 Receptor Agonist, Type 2 Diabetes

Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study

January 17th 2022

The switch from NPH insulin to Gla-300 improved glycemic control in older patients with T2D and in those with a longer disease duration. Older patients with T2D and those with a longer disease duration benefited even more from the switch to Gla-300 than younger patients and those with a shorter disease duration, with significantly greater reductions in the risk of hypoglycemia (Diabetes Therapy)

Categories: Medication, News, Treatment
Tags: insulin, Type 2 Diabetes

Categories: Medication, Treatment
Tags: insulin, Type 2 Diabetes

Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial

January 13th 2022

(i) At EOS T2DM subjects treated with Triple Therapy had less hepatic steatosis and fibrosis versus Conventional Therapy; (ii) severity of hepatic steatosis and fibrosis both were strongly and inversely correlated with insulin resistance; (iii) changes in liver fibrosis scores (APRI, NFS, FIB-4, AST/ALT ratio) have limited value in predicting response to therapy (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: exantide, fibrosis, hepatic steatosis, metformin, pioglitazone, steatosis

Categories: Medication
Tags: exantide, fibrosis, hepatic steatosis, metformin, pioglitazone, steatosis

Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes

January 5th 2022

The development of high-dose GLP-1 RAs and dual GLP-1/GIP-RA tirzepatide resulted in increasing numbers of people reaching HbA1c and bodyweight targets, with up to 62% attaining normoglycaemia with 15 mg tirzepatide. Whether this will also translate in better cardiovascular outcomes and will affect treatment guidelines remains to be studied (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP-1, GLP-1/GIP, GLP-1/glucagon receptor agonists, Type 2 Diabetes

Categories: Medication
Tags: GLP-1, GLP-1/GIP, GLP-1/glucagon receptor agonists, Type 2 Diabetes

Combined SGLT-2 and ACE inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial

January 5th 2022

A distinct RAS modulation by SGLT-2i occurs in diabetic kidney disease reflected by enhancement of the beneficial Angiotensin-(1–7) providing a molecular background for this renoprotective therapeutic approach (Diabetes, Obesity and Metabolism)

Categories: Medication, Nephropathy, News
Tags: ACE inhibition, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: ACE inhibition, SGLT2 inhibitors, Type 2 Diabetes
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 52
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Novo NordiskNapp DiabetesAstraZenecaBoehringer Ingelheim

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership